SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin’s Mandideep Unit-2 Facility completes USFDA inspection with No Observations

14 Aug 2023 Evaluate

Lupin’s Unit-2 manufacturingfacility located in Mandideep, India, has successfully completed a GMP inspection by the United States Food and Drug Administration (USFDA). The inspection was conducted from August 7 to August 11, 2023 and concluded without any observations. 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.


Lupin Share Price

2273.65 -104.25 (-4.38%)
11-May-2026 14:18 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1873.00
Dr. Reddys Lab 1289.40
Cipla 1307.55
Zydus Lifesciences 953.55
Lupin 2273.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×